- Home
- SNGX vs VRAX Comparison
SNGX vs VRAX Comparison
Compare SNGX & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNGX | VRAX |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 1.7M |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SNGX | VRAX |
|---|---|---|
| Price | $1.14 | $0.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $1.00 |
| AVG Volume (30 Days) | 176.0K | ★ 6.0M |
| Earning Date | 05-08-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,371.00 | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.13 |
| 52 Week High | $6.23 | $1.34 |
Technical Indicators
Market Signals| Indicator | SNGX | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 39.85 |
| Support Level | $1.01 | N/A |
| Resistance Level | $1.47 | $0.26 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 58.47 | 14.61 |
Price Performance
Historical ComparisonAbout SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.